INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after treatment with intravenous artesunate in patients with severe malaria. Little is known about its frequency and the outcomes of patients with this condition. METHODS: A retrospective study was conducted to describe the incidence of delayed haemolysis in a cohort of patients with severe malaria by Plasmodium falciparum treated with artesunate between August 2013 and July 2015. RESULTS: The study included 52 patients with malaria due to Plasmodium falciparum, with 21 having severe malaria. The majority were male ...
Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunat...
Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunat...
Background: Hemolysis is common in malaria infection and during the course of treatment. Previous s...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after tr...
BACKGROUND: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Rem...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
SummaryBackgroundArtemisinin derivatives are the mainstay of antimalarial treatment, both for uncomp...
French Artesunate Working GroupInternational audienceArtesunate is the most effective treatment for ...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
International audienceBACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT)...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
International audienceWe read with interest the article by Rehman et al. on post-artesunate hemolysi...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
As a result of a huge effort of the international community, the burden of malaria dropped impressiv...
Abstract Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, h...
Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunat...
Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunat...
Background: Hemolysis is common in malaria infection and during the course of treatment. Previous s...
INTRODUCTION: Delayed haemolytic anaemia is one of the more frequent events after tr...
BACKGROUND: Delayed haemolysis is a frequent adverse event after treatment with artesunate (AS). Rem...
International audienceBackground: Parenteral artesunate is recommended as first-line therapy for sev...
SummaryBackgroundArtemisinin derivatives are the mainstay of antimalarial treatment, both for uncomp...
French Artesunate Working GroupInternational audienceArtesunate is the most effective treatment for ...
Artesunate is the drug of choice for treating patients with severe malaria. Post-artesunate delayed ...
International audienceBACKGROUND: In sub-Saharan Africa, artemisinin-based combination therapy (ACT)...
Abstract Parenteral artesunate has been shown to be a superior treatment option compared to parenter...
International audienceWe read with interest the article by Rehman et al. on post-artesunate hemolysi...
Parenteral artesunate (AS) is the WHO first-line treatment recommended in adults and children for se...
As a result of a huge effort of the international community, the burden of malaria dropped impressiv...
Abstract Background Parenteral artesunate is the treatment of choice for severe malaria. Recently, h...
Episodes of delayed hemolysis 2–6 weeks after treatment of severe malaria with intravenous artesunat...
Episodes of delayed hemolysis 2-6 weeks after treatment of severe malaria with intravenous artesunat...
Background: Hemolysis is common in malaria infection and during the course of treatment. Previous s...